公开(公告)号：US12083093B2

公开(公告)日：2024-09-10

申请号：US17413088

申请日：2019-10-11

申请人： RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY

发明人： Jae-Ryong Kim ,  Eok-Cheon Kim ,  Kyong-Jin Jung ,  You Lim Son

IPC分类号： A61K31/35 ,  A61P9/10 ,  A61P11/00 ,  A61P13/12 ,  A61P19/04 ,  A61P27/02

CPC分类号： A61K31/35 ,  A61P9/10 ,  A61P11/00 ,  A61P13/12 ,  A61P19/04 ,  A61P27/02

摘要： The present invention relates to a composition for preventing or treating cellular senescence-associated diseases comprising salinomycin as an active ingredient, which acts differently depending on the type of senescent cells, and it was confirmed that salinomycin exhibits a senomorphics effect of restoring the function and morphology of fibroblasts and vascular endothelial cells in which senescence is induced and exhibits a senolytics effect of selectively killing aging-induced retinal pigmented epithelial cells, and exhibits a senomorphics effect of restoring the function and morphology of cells, and thus the salinomycin acts differently depending on the type of cells to effectively prevent or treat senile eye disease, tissue fibrosis disease, atherosclerosis, osteoarthritis, degenerative brain disease, chronic skin damage, obesity and diabetes caused by cellular aging and can be provided as a composition for life extension.

公开(公告)号：US20240293464A1

公开(公告)日：2024-09-05

申请号：US18287554

申请日：2022-04-20

申请人： Mohamed Hamza NOORDEEN

发明人： Mohamed Hamza NOORDEEN

IPC分类号： A61K35/28 ,  A61K31/203 ,  A61P17/02 ,  A61P19/04

CPC分类号： A61K35/28 ,  A61K31/203 ,  A61P17/02 ,  A61P19/04

摘要： Compounds, compositions, combined preparations, and multiple-dose formulations, for use in the treatment of tissue damage or injury, in particular, for example, spinal cord injury and tendon injury, are described. Methods of treatment of tissue damage or injury using the compounds, compositions, combined preparations, or multiple-dose formulations, are also described. Vitamin A. and optionally one or more regenerative cells, is used to inhibit scar tissue formation in a subject, which is a necessary prerequisite for successful tissue regeneration following tissue damage or injury. Vitamin A and compositions comprising vitamin A, for use in the treatment of pulmonary fibrosis, including pulmonary fibrosis caused by respiratory infection, are also described. Methods of treatment of pulmonary fibrosis using vitamin A and compositions are also described. Vitamin A. and compositions, combined preparations, and multiple-dose formulations comprising vitamin A, for use in the treatment of acute and chronic traumatic brain injury are also described, as well as methods of treatment of such injury using vitamin A. or the compositions, combined preparations, or multiple-dose formulations.

公开(公告)号：US11926596B2

公开(公告)日：2024-03-12

申请号：US16632659

申请日：2018-07-23

申请人： KADMON CORPORATION, LLC

发明人： Eduardas Skucas ,  Kevin G. Liu ,  Ji-In Kim ,  Masha V. Poyurovsky ,  Rigen Mo ,  Jingya Zhang

IPC分类号： C07D231/56 ,  A61P19/04 ,  A61P25/28 ,  C07D401/12 ,  C07D403/12

CPC分类号： C07D231/56 ,  A61P19/04 ,  A61P25/28 ,  C07D401/12 ,  C07D403/12

摘要： The invention relates to inhibitors of ROCK1 and/or ROCK2 having the formula I:




Also provided are methods of inhibiting ROCK1 and/or ROCK2 useful for the treatment of disease.

公开(公告)号：US20230313136A1

公开(公告)日：2023-10-05

申请号：US18120301

申请日：2023-03-10

申请人： Children's Medical Center Corporation

发明人： Markus H. Frank

IPC分类号： C12N5/071 ,  A61K35/36 ,  C12N5/0775 ,  A61P19/04 ,  A61P19/08

CPC分类号： C12N5/0625 ,  A61K35/36 ,  C12N5/0668 ,  A61P19/04 ,  A61P19/08

摘要： The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

公开(公告)号：US20230277601A1

公开(公告)日：2023-09-07

申请号：US17620154

申请日：2021-05-04

申请人： Tego Science Inc.

发明人： Saewha JEON ,  Jikhyon HAN ,  Yun Hee KIM ,  Ji-Hye LEE

IPC分类号： A61K35/33 ,  A61K47/36 ,  A61P19/04 ,  C12N5/077

CPC分类号： A61K35/33 ,  A61K47/36 ,  A61P19/04 ,  C12N5/0656

摘要： The present invention relates to human skin-derived fibroblasts having a tendon regeneration effect and a pharmaceutical composition for regenerating and treating a tendon, and the allogeneic skin-derived fibroblasts may have similar cell morphology to tenocytes, have a high expression level of vimentin, which is a fibroblast marker, express a large amount of extracellular matrix proteins, TGF-β, and increase collagen synthesis by acting on an ERK signaling mechanism, thereby effectively regenerating an injured tendon.

公开(公告)号：US20230226120A1

公开(公告)日：2023-07-20

申请号：US17929813

申请日：2022-09-06

申请人： SCICOTEC GMBH

发明人： Eckhard U. ALT

IPC分类号： A61K35/545 ,  C12N5/0775 ,  A61P19/04

CPC分类号： A61K35/545 ,  C12N5/0667 ,  A61P19/04

摘要： A composition comprising isolated vascular-associated naturally pluripotent stem cells (vaPS), is disclosed, as well as method of treating defects using such composition, wherein said vaPS are capable of differentiating into somatic cells of all three germ layers under the guidance of the respective microenvironment.

公开(公告)号：US20230190821A1

公开(公告)日：2023-06-22

申请号：US17919453

申请日：2021-04-16

申请人： CROWN SCIENTIFIC, L.L.C.

发明人： Ramon Coronado

IPC分类号： A61K35/50 ,  A61K35/28 ,  A61K31/557 ,  A61P37/06 ,  A61P9/00 ,  A61P17/00 ,  A61P19/04 ,  A61P31/14 ,  A61P11/00 ,  A61K45/06 ,  C12N5/0735

CPC分类号： A61K35/50 ,  A61K35/28 ,  A61K31/557 ,  A61P37/06 ,  A61P9/00 ,  A61P17/00 ,  A61P19/04 ,  A61P31/14 ,  A61P11/00 ,  A61K45/06 ,  C12N5/0606 ,  C12N2500/02

摘要： The disclosure provides nonsteroidal anti-inflammatory compositions and methods of use thereof. Specifically, the disclosure provides cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory compositions derived from placenta and/or from MSC cells isolated therefrom, methods for producing said compositions, and uses thereof to treat chronic and acute inflammatory conditions and diseases.

公开(公告)号：US20230149503A1

公开(公告)日：2023-05-18

申请号：US17916337

申请日：2021-03-31

申请人： The Regents of the University of California

发明人： Arjun Deb

IPC分类号： A61K38/12 ,  A61P17/02 ,  A61P19/04

CPC分类号： A61K38/12 ,  A61P17/02 ,  A61P19/04

摘要： The present disclosure relates to compositions and methods for treating a dysregulated wound healing, for improving wound healing, for inhibiting scar formation, for treating a subject with Ehlers Danlos syndrome (EDS), and for treating a subject diagnosed with a heart attack. The present disclosure further relates to compositions and methods for predicting future cardiac risk in a subject who has suffered a heart attack, and predicting risk of future cardiac disease in a subject suffering a heart attack.

公开(公告)号：US20190216781A1

公开(公告)日：2019-07-18

申请号：US16308012

申请日：2017-06-08

申请人： Clementia Pharmaceuticals Inc.

发明人： Clarissa DESJARDINS ,  Donna Roy GROGAN ,  Jeffrey Neal PACKMAN ,  Mark HARNETT

IPC分类号： A61K31/415 ,  A61P19/08 ,  A61P19/04 ,  A61K9/00

CPC分类号： A61K31/415 ,  A61K9/0014 ,  A61K9/0053 ,  A61K31/00 ,  A61K45/06 ,  A61P19/04 ,  A61P19/08

摘要： The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.

公开(公告)号：US20190211023A1

公开(公告)日：2019-07-11

申请号：US16311979

申请日：2017-06-29

申请人： Jianming YIN ,  HANGZHOU SANYINTAI PHARMACEUTICAL TECHNOLOGY CO., LTD.

发明人： Jianming YIN ,  Yubin LV ,  Bangliang LI

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  A61K31/4985 ,  A61P3/10 ,  A61P11/06 ,  A61P19/02 ,  A61P19/04 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/08

摘要： Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.